Abstract
Almost thirty percent of the protein targets currently under exploration and study constitute the protein kinases which have always attracted the pharmaceutical companies as they are easy targets for drug development. Although the kinases will remain major focus of oncology for many years to come in the development of anticancer drugs, the number of kinase inhibitors as therapeutic targets for the treatment of several other diseases which are undergoing clinical trials are exponentially increasing. In this review, we discuss very briefly the different types of protein kinases that have been used as targets for developing drugs for cancer, inflammation, autoimmune disease, heart disease and animal diseases.
Keywords: Cancer, inflammatory and autoimmune diseases, kinases, protein kinases.
Current Enzyme Inhibition
Title:Protein Kinases as Drug Targets in Human and Animal Diseases
Volume: 13 Issue: 2
Author(s): Suvarna G. Kini*, Vikas Garg, Sharada Prasanna, Revathi Rajappan and Muhammad Mubeen
Affiliation:
- Manipal College of Pharmaceutical Sciences, Manipal University, Manipal-576104, Karnataka,India
Keywords: Cancer, inflammatory and autoimmune diseases, kinases, protein kinases.
Abstract: Almost thirty percent of the protein targets currently under exploration and study constitute the protein kinases which have always attracted the pharmaceutical companies as they are easy targets for drug development. Although the kinases will remain major focus of oncology for many years to come in the development of anticancer drugs, the number of kinase inhibitors as therapeutic targets for the treatment of several other diseases which are undergoing clinical trials are exponentially increasing. In this review, we discuss very briefly the different types of protein kinases that have been used as targets for developing drugs for cancer, inflammation, autoimmune disease, heart disease and animal diseases.
Export Options
About this article
Cite this article as:
Kini G. Suvarna*, Garg Vikas, Prasanna Sharada, Rajappan Revathi and Mubeen Muhammad, Protein Kinases as Drug Targets in Human and Animal Diseases, Current Enzyme Inhibition 2017; 13 (2) . https://dx.doi.org/10.2174/1573408013666161128144216
DOI https://dx.doi.org/10.2174/1573408013666161128144216 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Effects of Sevoflurane or Remifentanil on the Stress Response to Surgical Stimulus
Current Pharmaceutical Design Nutritional Interventions and Primary Prevention of Type 2 Diabetes
Current Nutrition & Food Science The Heart Metabolism: Pathophysiological Aspects in Ischaemia and Heart Failure
Current Pharmaceutical Design Review on Bosentan, A Dual Endothelin Receptor Antagonist for the Treatment of Pulmonary Arterial Hypertension
Recent Patents on Cardiovascular Drug Discovery Primary Prevention of Ischaemic Stroke in Atrial Fibrillation: New Oral Anticoagulant Drugs for all?
Current Vascular Pharmacology Engineered Probiotic and Prebiotic Nutraceutical Supplementations in Combating Non-communicable Disorders: A Review
Current Pharmaceutical Biotechnology Tofacitinib, an Oral Janus Kinase Inhibitor: Perspectives in Dermatology
Current Medicinal Chemistry Treatment and Response to Statins: Gender-related Differences
Current Medicinal Chemistry Antagonism by Bioactive Polyphenols Against Inflammation: A Systematic View
Inflammation & Allergy - Drug Targets (Discontinued) Redefining the Role of Long-Acting Phosphodiesterase Inhibitor Tadalafil in the Treatment of Diabetic Erectile Dysfunction
Current Diabetes Reviews Modifiable Midlife Risk Factors for Late-Life Cognitive Impairment and Dementia
Current Psychiatry Reviews Hemostatic Factors and the Metabolic Syndrome
Current Vascular Pharmacology Effective Agents Targeting the Mitochondria and Apoptosis to Protect the Heart
Current Pharmaceutical Design Cardiovascular Disease in Systemic Lupus Erythematosus: Recent Data on Epidemiology, Risk Factors and Prevention
Current Vascular Pharmacology Recent Advances in Ozonation of Vegetable Oils
Recent Patents on Materials Science Understanding Respiratory Syncytial Virus Infection to Improve Treatment and Immunity
Current Molecular Medicine Is the Evolutionary Programmed/ Non-programmed Aging Argument Moot?
Current Aging Science Recent Advances in Antiarrhythmic Drug Treatment of Atrial Fibrillation
Recent Patents on Cardiovascular Drug Discovery Screening of Novel Inhibitors Against Leishmania donovani Calcium ion Channel to Fight Leishmaniasis
Infectious Disorders - Drug Targets Endothelial Dysfunction, Impaired Endogenous Platelet Inhibition and Platelet Activation in Diabetes and Atherosclerosis
Current Vascular Pharmacology